In Phoenix, the Parkinson’s World Searches for Hope

The desert heat feels almost unreal here.

Outside the convention centre in Phoenix, the air is dry enough to sting. Inside, thousands of people move continuously through the halls of the World Parkinson Congress 2026 — neurologists, researchers, physiotherapists, caregivers, patient advocates and people living with Parkinson’s disease.

The scale of the congress is striking. So is the relative silence surrounding it outside these walls.

Parkinson’s is now widely described as the world’s fastest-growing neurological disease, yet the gathering still exists largely outside mainstream international attention. Few television crews crowd the entrances. Few political delegations move through the halls. Outside specialist circles, the disease still occupies surprisingly little space in public conversation relative to its scale.

And yet for the people here, Parkinson’s shapes nearly everything.

Not only movement, but sleep, cognition, mood, energy, speech and identity. The disease progresses unevenly and unpredictably. Some remain functional for decades. Others decline rapidly. No two trajectories look entirely alike. That uncertainty hangs over the congress as much as the science itself.

I am here as a journalist. But also because Parkinson’s has become part of my own family’s reality. My brother lives with the disease. Together, this week, we are launching The Initiative - a publication built around Parkinson’s, neurodegenerative disease and the growing gap between scientific complexity and public understanding.

In many ways, this congress explains why we felt the need to build it. The amount of information surrounding Parkinson’s is enormous. Biomarkers. Stem-cell therapies. Alpha-synuclein biology. Genetics. Exercise science. Clinical subtypes. Early detection. AI-driven monitoring.

But for many patients and families, the knowledge exists in fragments - technically dense, scattered across journals and often inaccessible without scientific training. At WPC2026, that fragmentation becomes visible in real time.

In one room, researchers debate biomarkers capable of identifying Parkinson’s years before classical motor symptoms emerge. In another, patients discuss medication side effects and the practical economics of long-term care. Downstairs, physiotherapists demonstrate balance training and movement exercises. In hotel lobbies late at night, conversations shift between cautious optimism and private fear.

The emotional distance between science and lived reality feels unusually small here.

For years, Parkinson’s research largely revolved around symptom management. Drugs such as levodopa remain highly effective for many patients, particularly early in the disease. Deep brain stimulation has transformed life for some. Exercise and multidisciplinary care have become increasingly central. But the larger ambition - slowing or interrupting the disease itself - has remained elusive. That is part of why the atmosphere in Phoenix feels different this year.

Several developments dominate discussion throughout the congress: rapid advances in alpha-synuclein testing, growing interest in earlier diagnosis, gene-targeted therapies aimed at specific patient groups and increasing recognition that Parkinson’s may need to be understood less as a single disease than as several biologically distinct disorders.

The implications are profound. If Parkinson’s is really a collection of overlapping syndromes with different biological drivers, progression patterns and treatment responses, then future treatment may become far more individualized than the field once imagined.

And yet, despite all the scientific ambition, caution remains everywhere.Which is why many experienced researchers here speak carefully. They talk less about cures than trajectories. Less about  breakthroughs than signals. The language is increasingly sophisticated, but also notably restrained.

That restraint reflects something difficult but important: The biology of Parkinson’s appears more complicated than researchers once believed. Even defining Parkinson’s itself is becoming less straightforward. Increasingly, scientists describe it not as a single condition, but as a broad spectrum of related disorders sharing similar outward symptoms.

For patients, however, complexity does not reduce urgency. Quite the opposite. The people moving through these halls are not abstract participants in a scientific debate. Many are navigating a progressive disease medicine still cannot stop. That reality creates a particular intensity around information itself.

People search constantly. Clinical trials. Exercise programmes. Nutrition strategies. Medication adjustments. Biomarkers. Experimental therapies. Hope becomes operational. And increasingly, many people with Parkinson’s feel they must become active participants in navigating their own disease rather than passive recipients of care. That instinct is visible everywhere in Phoenix. In the questions asked after scientific sessions. In conversations between strangers waiting for coffee. In discussions about exercise, sleep, stress reduction and self-management. In the way patients study researchers almost as closely as researchers study the disease itself.

For a few days, the global Parkinson’s community compresses into a single place. Then it disperses again. Whether WPC2026 will ultimately be remembered as a genuine turning point in Parkinson’s research remains impossible to know. The science is advancing. Expectations are rising. But uncertainty still dominates many of the most important questions.

And perhaps that, more than anything else, defines the atmosphere here in the Arizona desert.